CEL-SCI Corporation, a clinical stage cancer immunotherapy company, has announced the pricing of its underwritten public offering of 2,000,000 shares of common stock at $2.50 per share. The offering is expected to generate gross proceeds of $5,000,000, before expenses. An additional option has been granted to underwriters to purchase up to 190,000 more shares to cover over-allotments. The offering aims to support the ongoing development of CEL-SCI's Multikine product, as well as general corporate purposes and working capital. ThinkEquity is acting as the sole book-running manager. The securities are being offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.